Compare Adobe Systems Inc (ADBE) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Bristol-Myers Squibb Co — how do they compare? Adobe Systems Inc trades at $220.47 (market cap $88.06B), while Bristol-Myers Squibb Co trades at $57.82 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 4.35% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | BMY | |
|---|---|---|
Market Cap | $88.06B | $118.38B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $62.37 |
52-Week Low | $193.41 | $42.60 |
Enterprise Value | $89.50B | $154.32B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.92, up 1.31% with a bullish technical signal despite recent volatility. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $5.96 versus $5.82, revenue growth to $23.77B in 2025, and robust profitability margins. However, negative net cash flow of -$2.18B in 2025 and AI competition concerns from recent news create mixed sentiment.
Outlook remains positive with a consensus price target of $246.75, representing 11.7% upside, supported by 49.21% analyst buy ratings. Key risks include AI disruption fears and CEO transition uncertainty, but Adobe's entrenched market position and double-digit growth provide a solid foundation for long-term investors.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
